Logo

Alector's AL101 Receives FDA's Fast Track Designation to Treat Frontotemporal Dementia

Share this

Alector's AL101 Receives FDA's Fast Track Designation to Treat Frontotemporal Dementia

Shots:

  • The US FDA has granted FT designation to Alector’s AL101 to treat patients with progranulin gene mutations causative of frontotemporal dementia (FTD-GRN)- currently being evaluated in P-I study in healthy volunteers
  • The FDA’s FT designation is designed to facilitate the development and expedite the review of therapies for serious conditions targeting unmet medical needs of patients
  • AL101 is a mAb- designed to restore levels of progranulin in the CNS- currently in development for FTD-GRN- AD and PD and has received FDA’s ODD for FTD-GRN in July’2019

Click here ­to­ read full press release/ article | Ref: Alector | Image: Alector


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions